2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - La Nouvelle A-B
Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Clinical Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Young Adult
PAPER

542 Ciltacabtagene autoleucel across lines of therapy in relapsed/refractory multiple myeloma: Earlier-line use is associated with deeper responses and favorable progression-free survival, while clinically significant toxicities are comparable

Doris K. Hansen, MD, Alicia Richards, PHD, MS2, Andrew J. Portuguese, MD3, Lauren C Peres, PhD, MPH4, Saurabh Zanwar, MBBS, MD5, Danai Dima, MD6, Lekha Mikkilineni, MD, MA7, Mahmoud R. Gaballa, MD8, Omar Alexis Castaneda Puglianini, MD9, Ariel F. Grajales-Cruz, MD10, Ricardo Daniel Parrondo, MD11, Aimaz Afrough, MD12, Shonali Midha, MD13, Christopher Ferreri, MD14, Cindy Varga, MD15, Francesca Cottini, MD16, Melinda Tan17, Christopher Cahoon, PharmD18, James A Davis, PharmD, BCOP19, Susan Bal, MD20, Sneha Purvey, MD21, Karen Sweiss, PharmD22, Asya Varshavsky, MD23, Hitomi Hosoya, MD, PhD24, Lorenzo Gensini, MD25, Sharlene Dong, MD, MS26, Jennifer Ann Kanakry, MD27, Megan M Herr, PhD28, Chenyu Lin, MD29, Omar Nadeem, MD30, Binoy Yohannan, MD31, Timothy O'Brien, MD32, Noa Biran, MD33, Marcus Geer, MD34, Rahul Banerjee, MD, FACP35, Ran Reshef, MD36, Doug W. Sborov, MD, MS37, Ashley Rosko, MD38, Ciara Louise L Freeman, MD, PhD39, Kenneth H. Shain, MD, PhD40, Saurabh Chhabra, MD, MBBS41, Larry D Anderson Jr, MD, PhD42, Hira Mian, MD43, Nisha Joseph, MD44, Frederick L. Locke, MD45, Luciano J. Costa, MD, PhD46, Yi Lin Jr, MD, PhD47, Krina Patel Jr, MD, MSc48, Surbhi Sidana, MD49, Oren Pasvolsky, MD50
1 Moffitt Cancer Center, Tampa, Florida, United States
2 Moffitt Cancer Center, Tampa, Florida, United States
3 Fred Hutchinson Cancer Center, Seattle, Washington, United States
4 Moffitt Cancer Center, Tampa, Florida, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Fred Hutchinson Cancer Center, Seattle, Washington, United States
7 Stanford University School of Medicine, Stanford, California, United States
9 Moffitt Cancer Center, Tampa, Florida, United States
10 Moffitt Cancer Center, Tampa, Florida, United States
11 Mayo Clinic-Florida, Jacksonville, Florida, United States
12 University of Texas Southwestern Medical Center, Dallas, Texas, United States
13 Division of Myeloma, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
14 Levine Cancer Institute, Charlotte, North Carolina, United States
15 Levine Cancer Institute, Charlotte, North Carolina, United States
16 The Ohio State University, Columbus, Ohio, United States
17 Mayo Clinic, Rochester, Minnesota, United States
18 Huntsman Cancer Institute, Salt Lake City, Utah, United States
19 Medical University of South Carolina, Charleston, South Carolina, United States
20 University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, Alabama, United States
21 Virginia Commonwealth University Massey Comprehensive Cancer Center, Richmond, Virginia, United States
22 University of Illinois at Chicago, Chicago, Illinois, United States
23 Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
24 Cedars-Sinai Medical Center, Los Angeles, California, United States
25 UT MD Anderson Cancer, Houston, Texas, United States
26 UT MD Anderson Cancer, Houston, Texas, United States
27 MedStar Georgetown University Hospital, Washington, D.C., United States
28 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
29 Duke Cancer Institute, Durham, North Carolina, United States
30 Division of Myeloma, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
31 University of Minnesota, Minneapolis, Minnesota, United States
32 University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States
33 John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States
34 University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
35 Fred Hutchinson Cancer Center, Seattle, Washington, United States
36 Herbert Irving Comprehensive Cancer Center, Columbia University, New York City, New York, United States
37 Huntsman Cancer Institute, Salt Lake City, Utah, United States
38 The Ohio State University, Columbus, Ohio, United States
39 Moffitt Cancer Center, Tampa, Florida, United States
40 Moffitt Cancer Center, Tampa, Florida, United States
41 Mayo Clinic Comprehensive Cancer Center, Phoenix, Arizona, United States
42 University of Texas Southwestern Medical Center, Dallas, Texas, United States
43 McMaster University, Hamilton, Ontario, Canada
44 Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia, United States
45 Moffitt Cancer Center, Tampa, Florida, United States
46 University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, Alabama, United States
47 Mayo Clinic, Rochester, Minnesota, United States
48 UT MD Anderson Cancer, Houston, Texas, United States
49 Stanford University School of Medicine, Stanford, California, United States
50 UT MD Anderson Cancer, Houston, Texas, United States

Introduction. Ciltacabtagene autoleucel (cilta-cel) has demonstrated remarkable efficacy and improved progression-free and overall survival (PFS, OS) in relapsed/refractory multiple myeloma (RRMM), leading to regulatory approval in earlier lines of therapy. Here we compare efficacy, survival, and safety of patients treated with standard-of-care (SOC) cilta-cel in earlier versus later lines of therapy in a multicenter U.S. cohort. 

Methods. Data were from a retrospective cohort of RRMM patients with the intent to receive SOC cilta-cel across 23 institutions in the U.S. Multiple Myeloma Immunotherapy Consortium. Analyses included patients leukapheresed from April 8, 2024–September 25, 2025, to capture the time-period of FDA approval of cilta-cel in the early-line setting. A covariate-adjusted inverse probability of treatment weighting (IPTW) approach was used to compare outcomes by prior line of therapy (pLOT; early-line: 1–2 pLOT vs. late-line: ≥3 pLOT) balancing on age, sex, race and ethnicity, ECOG performance status (PS), triple-class exposure, extramedullary disease, high-risk cytogenetics (adapted IMS/IMWG consensus criteria: del17p; t(4;14) or t(14;16) with gain1q or del1p; or gain1q with del1p), functional high-risk disease (relapse ≤ 18 months of first-line therapy), baseline ferritin, and bridging therapy response. Logistic and Cox proportional hazards regression models incorporating IPTW weights were used to examine the association of treatment line with efficacy, survival, and safety. We employed propensity score matching of the same covariates to identify the association of line of therapy with PFS within relevant patient subgroups.

Results. A total of 1233 patients were leukapheresed with cilta-cel in early-line (n=348) and late-line (n=885). Of those,1160 patients were infused (n=335 early-line; n=825 late-line) with a median follow-up of 10.6 and 11.7 months, respectively. After IPTW, patient characteristics were well-balanced (standardized mean differences < 0.1). Early-line cilta-cel was associated with higher odds of achieving day 90 ≥ partial response (PR; OR=2.89, 95% CI=1.47-5.69) and ≥ complete response (OR=1.44, 95% CI=1.07-1.94) compared with late-line cilta-cel. The estimated 12-month PFS was 82.6% in the early-line group vs 75.5% in the late-line group. Although not statistically significant, early-line cilta-cel was associated with longer PFS and OS compared with late-line (HR=0.71, 95% CI=0.50-1.01; HR=0.73, 95% CI=0.46-1.16, respectively). Results for PFS and OS were consistent in the intention-to-treat cohort (PFS: HR=0.73, 95% CI=0.52-1.04; OS: HR=0.76, 95% CI=0.48-1.20). When exploring associations stratifying the early-line group into 1 vs 2 pLOTs, patients with 1 pLOT had better PFS and OS compared with ≥ 3 pLOT (HR=0.30, 95% CI=0.10-0.90; HR=0.45, 95% CI=0.10-2.10, respectively). In a propensity-matched cohort (n=624; 312 early-line and 312 late-line), early- vs late-line cilta-cel was associated with superior PFS among patients aged <70 years (p=0.04), an ECOG PS ≥2 (p=0.01), and high-risk cytogenetics (p=0.007), but no association was observed among their counterparts: patients aged ≥70 years (p=0.8), an ECOG PS <2 (p=0.5), and standard-risk cytogenetics (p=0.4).

Patients treated with early- vs late-line cilta-cel were more likely to have any grade cytokine release syndrome (CRS; OR=1.53, 95% CI=1.09-2.15) and any non-immune effector cell-associated neurotoxicity (NINT; OR=1.44, 95% CI=1.01-2.04), largely driven by cranial nerve palsies (CNP; OR=1.85, 95% CI=1.24-2.77). An elevated but non-significant odds of parkinsonism was observed for early- versus late-line cilta-cel (OR=1.50, 95% CI=0.73-3.07). CNP and parkinsonism occurred in 18% and 4.6% of early-line versus 10% and 2.7% of late-line patients, respectively. No significant differences in grade ≥3 CRS, any and grade ≥3 immune effector cell-associated neurotoxicity syndrome (ICANS), immune effector cell-associated enterocolitis (IEC-EC), cytopenias, severe infections, second primary malignancies, and non-relapse mortality (NRM) were observed.

Conclusion. Early-line SOC cilta-cel was associated with improved responses, favorable PFS, and a higher incidence of CNP, but no differences in parkinsonism, IEC-EC or NRM. This study provides valuable information regarding earlier-line use of cilta-cel in RRMM and may help inform patient selection, counseling, and treatment sequencing.

 

*DH, AR, AP, LP & †YL, KP, SS, OP: co-lead authors

 

Doris K. Hansen, MD: BMS - Research Funding; BMS, Janssen, Karyopharm, Kite Pharma, and Adaptive Biotech - Research Funding; Johnson & Johnson - Research Funding; Janssen - Research Funding; Adaptive - Research Funding; Kite - Research Funding; Karyopharm - Research Funding; Kite - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Karyopharm - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); BMS, Janssen, Legend Biotech, Pfizer, Kite Pharma/Gilead Sciences, AstraZeneca, and Karyopharm - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Legend biotech - Consultancy (Includes expert testimony)